Eli Lilly announces regulatory approval for insulin manufactured in Egypt

The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries, most of which are in Africa. Under this agreement, Lilly has been supplying its active pharmaceutical ingredient for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.